PEVIA Consortium Submits 1st Intermediate Report
1st June 2015 Evry, 01 June, 2015 – The consortium involving VAXEAL RESEARCH SAS, INSERM, The UNIVERSITY PARIS DESCARTES (PARIS 5), AP-HP, and the CEA, today announced that they have successfully reached the first milestone related to the pre-clinical development of SVX-1 Therapeutic Vaccine, and submitted the intermediate report to the French National Research Agency (ANR).SVX-1 is a tumor antigen over-expressed in most common human cancers whereas it is poorly expressed in most normal adult tissues. In tumor cells, this protein is essential for survival as it regulates both cell division and apoptosis.About VaxealCreated in 2009, Vaxeal Holding SA is an SME headquartered in Vevey (Switzerland). The company, in partnership with leading International Research Institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families. Our initial programs have reached the pre-clinical stage in major disease segments, and are expected to enter into clinical trials in Europe in 2016. Vaxeal is member of Vaccines Europe, and the European Biopharmaceutical Enterprises. The company received a special MIT award for “its remarkable breakthrough in the field of vaccines”.About the French National Research Agency (ANR)
The French National Research Agency was created in 2005 to organise the funding of projects whose end-purpose is to give impetus to the research sector. Firmly committed to addressing this issue, which is of crucial importance for the competitiveness of France and the international visibility of its research work, the ANR places great importance on: fostering creativity and openness, stimulating new ideas and partnerships, targeting research efforts on economic and societal priorities determined at the highest level of State and through consultation with the other research players, encouraging inter-disciplinary actions, intensifying links between the public and private sectors, developing international and European collaborations The main challenges the ANR works on are part of the European Strategic Agenda. Please visit www.agence-nationale-recherche.fr for more information.
About The UNIVERSITY PARIS DESCARTES
With its nine Training and research departments (UFR) and its Institute of Technology (IUT), Paris Descartes University encompasses all the fields of knowledge of human and health sciences. It is the only university of the Ile-de-France region to offer medical, pharmaceutical and odontological studies; its health department is renowned in Europe and in the whole world for the high quality of its training and the excellence of its research.
About The Assistance publique – Hôpitaux de Paris (AP-HP)
The Assistance publique – Hôpitaux de Paris (AP-HP) is the public hospital system (établissement public de santé) of the city of Paris and its suburbs. Its headquarters are in the 4th arrondissement of Paris. It is the largest hospital system in Europe and one of the largest in the world, it provides health care, teaching, research, prevention, education and emergency medical service in 52 branches of medicine. It employs more than 90,000 people (including 15,800 physicians) in 44 hospitals and receives more than 5,8 million annual patient visits.
The Institut national de la santé et de la recherche médicale is a French biomedical and public health research institution.
Created in 1964, the INSERM is a public institution with a scientific and technical vocation under the dual auspices of the Ministry of Health and the Ministry of Research. It was created as a successor to the French National Institute of Health. INSERM consists of 339 research units, run by 6,500 permanent staff members. Eighty percent of INSERM research units are embedded in research hospitals of French universities.
About The CEA
The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l’énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future.Ahmed Bouzidi, presented at the iProve workshop for therapeutic vaccines and SMEs organized by Vaccines Europe →← Ahmed Bouzidi, presented at the Stakeholder VAX 1-2-1 in Amsterdam